| Trial name or title |
Dose‐finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non‐Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST‐1) |
| Methods |
Parallel group randomized trial |
| Participants |
Patients with non‐cystic fibrosis bronchiectasis and pulmonary P Aeruginosa infection |
| Interventions |
tobramycin inhalation powder (TIP) dose and placebo, 3 dose regimens |
| Outcomes |
P aeruginosa density in sputum |
| Starting date |
2 February 2017 |
| Contact information |
Novartis Pharmaceuticals: email: trialandresults.registries@novartis.com |
| Notes |
Estimated completion date: 10 September 2018 |
